Exact Sciences Enhances Cancer Care with Comprehensive Precision Oncology Portfolio

Exact Sciences, a leader in cancer diagnostics, offers a comprehensive Precision Oncology portfolio designed to provide actionable genomic insights for cancer prognosis and treatment. The Oncotype DX Breast Recurrence Score test is a pivotal tool in breast cancer care, predicting chemotherapy benefits and recurrence risk in invasive breast cancer. Recognized as a standard of care, it is included in major treatment guidelines.

The OncoExTra test utilizes whole exome and transcriptome sequencing to assist in therapy selection for advanced cancer cases, encompassing a broad panel of approximately 20,000 genes. This test is vital for patients with metastatic, refractory, or recurrent cancers.

Additionally, the Riskguard hereditary cancer test offers personalized reports on genetic and familial cancer risks through simple blood or saliva samples, covering ten common cancers such as colorectal, breast, and prostate.

Exact Sciences is committed to empowering patients and healthcare providers by simplifying the process of ordering tests and interpreting results, ultimately enhancing personalized cancer treatment strategies.

For more information, visit Exact Sciences' Precision Oncology website.